Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses the value of pacritinib in the treatment of myelofibrosis (MF), drawing focus on the ability of this agent to improve red blood cell count in patients. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.